Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Abstract Background Osimertinib is a third-generation EGFR-TKI with a high selective potency against T790M-mutant NSCLC patients. Considering that osimertinib can lead to enhanced HER-2 expression on cell surface and HER-2 overexpression is a mechanism of resistance to osimertinib, this study was ad...

Full description

Bibliographic Details
Main Authors: Silvia La Monica, Daniele Cretella, Mara Bonelli, Claudia Fumarola, Andrea Cavazzoni, Graziana Digiacomo, Lisa Flammini, Elisabetta Barocelli, Roberta Minari, Nadia Naldi, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
NSCLC
EGFR
Osimertinib
T-DM1
TKI-resistance
Online Access:http://link.springer.com/article/10.1186/s13046-017-0653-7

Internet

http://link.springer.com/article/10.1186/s13046-017-0653-7

Similar Items